Introduction: The effect of opioids on driving performance has been much debated. Driving is a complex task requiring integration of psychomotor, cognitive, motor and decision-making skills, visualspatial abilities, divided attention, and behavioral and emotional control. The objective of this systematic review was to assess the quality of studies and to revisit the concept that patients on stable opioids are safe to drive as it applies to everyday practice.
C
hronic pain is one of the most significant issues in healthcare. Between 10% and 55% of people in western societies experience chronic noncancer pain. 1 Chronic pain may impair numerous aspects of one's existence resulting in unemployment, disability, disruption of social roles, and impaired quality of life. 2 Driving is a complex task as individuals are required to integrate psychomotor and cognitive skills, visual-spatial abilities, decision making, divided attention, motor skills, and behavioral and emotional control 3 The role of opioids on driving performance has been much debated. Opioid treatment studies have demonstrated inconsistent influence on driving ability. A systematic review conducted in 2003 4 looked at 48 studies with specific attention to tests measuring visual processing, attention, psychomotor abilities, postural imbalance, and cognitive function. The investigators stated that they studied individuals on "stable opioids," though they provided no specific definition as to what stable opioids mean, and concluded that "opioids appear not to impair driving skills in opioid dependent patients" (pp 574). Nevertheless, they reported inconclusive evidence from multiple studies on the cognitive function of opioid maintained patients (pp 559), and remarked on the need for further studies to conclusively answer whether patients on long-term opioids have impaired driving skills. This review included studies on healthy volunteers or opioid-addicted patients without pain in addition to pain patients. Therefore, the results cannot be generalized to the patients who are prescribed opioids for chronic cancer or noncancer pain.
The most recent published review 5 looked specifically at chronic noncancer pain patients treated with opioids for at least 1 month. Altogether, 13 studies were found (3 randomized controlled trials, 2 nonrandomized comparative trials, and 8 observational studies classified as outcomes research). The authors concluded that "y. current evidence for benefit, harm or lack of appreciable effect of a long term stable opioid treatment on cognitive functioning in chronic non cancer pain patients is still limited" (pp 229), a result similar to that of the previous review. 4 They suggested the creation of "international collaboratives to propose and organize focused research activities in the field" (pp 230).
The variable results in the current literature with regard to opioids and driving may be due to a multiplicity of factors including pain severity, combinations of medications, sleep disturbance and fatigue, comorbid psychiatric and psychological disorders, or other factors. Although some studies have found that opioids do not impair psychomotor performance, [6] [7] [8] [9] other studies have concluded that chronic pain patients may have impaired cognitive function. [10] [11] [12] [13] [14] [15] It has been suggested that untreated pain by itself may pose a greater risk to cognitive function than opioids 16 and driving ability improves once the pain is treated with opioids.
Chronic pain is commonly associated with sleep disturbance and fatigue [18] [19] [20] and depressive, anxiety, or other psychological and psychiatric comorbidities. [21] [22] [23] [24] [25] [26] [27] [28] [29] Sleep disturbance, daytime sleepiness or fatigue, [30] [31] [32] [33] [34] [35] and psychological and psychiatric comorbidities [36] [37] [38] [39] are known to potentially interfere with cognitive functioning including driving ability. As well, several classes of pharmacologic agents used in the treatment of chronic pain and associated disorders may have adverse effects on driving ability. Drugs such as benzodiazepines, 40, 41 antidepressants, 36, 42, 43 anticonvulsants, 44 and opioids 45 have been shown to impair driving and increase the risk of traffic accidents. 46 The question "Can patients on opioids drive"? remains without a clear answer. There are increasing concerns about patients on long-term opioids and prescribers' liability in case such patients are involved in traffic accidents. 47 Therefore, we perceived the need to revisit the literature and attempt to outline which patients on opioids are safe to drive. The specific objectives of our systematic review were to scrutinize the existing literature on opioids, cognitive function, and driving ability relating to (1) methodological quality of existing studies specifically on chronic cancer and noncancer pain patients, (2) sensitivity and validity of cognitive and psychomotor tests used to assess the effects of opioids on cognition (often used as surrogate measures for driving ability), and (3) the reporting of other variables that may alter interpretation of study results and generalizability of the conclusions (such as other psychotropic drugs, sleep disorder, and daytime somnolence, mood or anxiety disorder, and level of pain), factors very prevalent and significant in patients with chronic pain.
METHODOLOGY Search Strategy
A comprehensive search of the following sources ( Fig. 1 
Inclusion Criteria
Two reviewers (S.F.L., B.Y.) screened all titles and abstracts for potential studies meeting specific inclusion and exclusion criteria. When eligibility could not be determined from the abstract, the full article was retrieved and reviewed and disagreements regarding eligibility were resolved by consensus. When in doubt, a third reviewer (A.F. or A.M.G.) was consulted.
Study design: Controlled studies with a concurrent or historical comparison group were included. 
Exclusion Criteria
We excluded studies conducted with patients on methadone maintenance treatment for addiction (unless methadone was specifically prescribed for chronic pain) and studies in which the pain was experimentally induced. Studies published only as abstracts were also excluded.
Data Extraction
The following data were extracted from all included studies: authors, publication year, country, study design, demographics of the population included, opioid intervention (type, dose, duration), control treatments, outcome measures, results (related to driving, cognitive function and psychomotor tests, pain relief, and sedation), and authors' main conclusion. Studies were considered to involve "unstable opioids" if measurements were performed after very short titration phase (<3 d), only short-acting opioids were administered or dosing schedule was poorly described. We summarized the data using both quantitative and qualitative methods.
Assessment of Sensitivity and Validation of the Cognitive Tests
All cognitive and psychomotor tests that may be used as surrogate measures of ability to drive were recorded and appraised by the senior psychologist (K.N.): (1) as to the sensitivity of functions tested in representing the "complex act of driving," and (2) whether they had been well validated or not. Cognitive tests were given a sensitivity score of 3 if they tested more complex functions (attention and cognitive flexibility) and stressed a component of processing speed, 3 2 for medium sensitivity functions and 1 for simpler functions that may not be very sensitive in capturing the complex act of driving. As most of the studies usually had more than 1 cognitive test, we calculated the mean of the sensitivity scores per study. For example, if a study had 3 cognitive tests with sensitivity scores of 3, 1, and 2, the mean of sensitivity scores for this study was 2. In addition, well-validated tests earned an A mark while poorly validated tests a score of B. Therefore, a cognitive test marked as 3(A) indicates a sensitive test of complex functions that has been well validated, whereas a test marked as 2(B) indicates a medium sensitivity or poorly validated test. We subsequently classified the neurocognitive tests in a dichotomous system, considering tests 2(A), 3(B), and 3(A) as better and more representative of driving abilities versus tests marked as 1(B), 1(A), or 2(B), which were considered poorer. The first group of tests will be referred to as high sensitivity and the second group as low sensitivity tests, respectively. Since most studies used batteries of tests, the number and proportion of high sensitivity versus low sensitivity tests was also calculated.
Assessment of Other Variables That May Affect Generalizability of Data
The clinician expert (A.M.G.) analyzed the retrieved studies for other confounding variables commonly present in everyday practice with chronic pain patients that may affect cognitive and psychomotor functions and driving ability. Given the nature and immense heterogeneity of the studies, "confounding variable points" were assigned to each of the studies to indicate the fact they did not take into account the presence of these factors that could alter driving ability by themselves. Such points were earned when: (1) pain severity or related measures were not mentioned; (2) other commonly prescribed drugs for chronic pain (antidepressants, antiepileptics, hypnotics and sedatives) were either not permitted or coprescriptions were not reported; (3) daytime somnolence or sleep disorder was not mentioned; and (4) significant mood, anxiety, or other psychiatric disorder was not assessed or reported.
Of note, this system makes no provisions to score for confounding variables that were mentioned but not controlled for in the conclusions of the studies. A maximum score of 4 in our system indicates, therefore, that none of the confounding variables listed above were mentioned in a given study. As very few if any studies actually mentioned AND controlled for these variables, "controlling for" was not part of our system scoring, which makes it extremely generous, underestimating the magnitude of confounders. Additional confounding variables if possible were recorded (eg, high variability in reported pain ratings, high level of placebo responses, poor reporting of patients or results, high dropout rate), though no score was given for these.
Methodological Quality Assessment
Two independent reviewers (B.Y., S.F.L.) assessed the methodological quality of each study and met to reach consensus and, in cases of disagreement, a third reviewer was consulted. For quality assessment, we used the Methodological Index for Nonrandomized Studies (MINORS) instrument to evaluate all studies, as it can also be applicable in randomized studies. 48 The MINORS methodological checklist contains 12 items. Each item is scored from 0 to 2 as follows: 0 = not reported, 1 = inadequately reported, or 2 = reported adequately in the evaluated article. Studies were classified as high (score 15 to 24), fair (score 11 to 14), or poor (score 10 or less) quality.
Statistical Analysis
Data analyses pertaining to sensitivity of tests assessing cognitive and psychomotor performance and MINORS scores were carried out using the SAS program version 9.2 (SAS Institute Inc., Cary, NC). Data were analyzed using the 2-sided Wilcoxon Mann-Whitney U test. The means of the sensitivity scores from all the studies were compared within the MINORS (poor, fair, and high) groups.
RESULTS
The initial search yielded 2054 studies; of these, 1920 titles and abstracts and another 15 studies generated through different sources, resulted in 127 hard copies retrieved. Altogether, 92 studies were excluded and 35 studies formed the basis for this review. [6] [7] [8] [9] 16, 45, Although we attempted to determine whether the studies used "stable" versus "unstable" opioid regimes, in none of the studies the term "stable opioids" was defined. We considered 11 of the 35 studies 52, 53, [57] [58] [59] 61, 62, [69] [70] [71] 74 as clearly using "unstable opioid doses" based on our definition (see Methods), whereas the rest of the studies were deemed to be using "stable doses" though at times information about the exact combination of long-acting and short-acting opioids was lacking. Ultimately, for the results of the study, stable or unstable opioid doses as defined here, did not really matter.
Ten of the studies were conducted in USA, 49 45, 71 and 1 study conducted in each of the following countries: Australia, 59 Brazil, 64 France, 77 Norway, 55 and UK. 6 The average dose of morphine or equivalent per day in milligrams was 119.68. However, there was a high-dose variability as the range of average doses was 16.3 to 210 mg, the range of minimum doses 6.6 to 130 mg, and the range of maximum doses 20.3 to 1110 mg. A total of 3724 individuals were included in the 35 studies (2044 patients on opioids, 523 of which were cancer patients, and 1994 controls). As for the methodological quality based on their MINORS score, 9% of the studies were of poor quality (3 of 35; mean score, 7.3 ± 2.08; MINORS range, 5 to 9), 54% of the studies were of fair quality (19 of 35; mean score, 13.6 ± 1.11; range, 11 to 14), and 37% of the studies were of high quality (13 of 35; mean score, 18.07 ± 1.93; range, 15 to 23).
Relating to the use of cognitive and psychomotor tests, 75% of the tests used in high-quality studies, 84% of the tests in fair quality studies, and 71% of the these in lowquality studies, were of higher sensitivity [2(A), 3(B), 3(A)]. Total mean sensitivity score for all included studies was 1.91 ± 0.47 (range, 0 to 2.4). When the mean sensitivity scores of the studies were compared based on the MINORS subgroups (low, fair, and high quality), no statistical differences were detected.
Analysis of "confounding variables" revealed that the majority of the studies were possibly affected by factors that could significantly alter the interpretation of the data. This is indicated by the fact that only 2 studies (6%) had no confounders based on our system; 29% of the studies (10 of 35) had 1 confounding variable, 29% of the studies (10 of 35) had 2 confounding variables, 31% of the studies (11 of 35) had 3 confounding variables, and 6% of the studies (2 of 35) had 4 confounding variables. The mean number of confounding variables was 2.2 with a range of 0 to 4. The methodological quality of the studies proved to be irrelevant to the number of confounding variables: highquality studies had a mean of 2.2 such variables, fair quality studies had a mean of 2.1, and low-quality studies had a mean of 2 confounding variables. The results are presented cumulatively in Table 1 .
Separate analysis was conducted in the 4 studies that tested driving on the road 53 or through a driving simulator, 58, 66, 75 which were considered superior to studies using only psychomotor and cognitive tests. Except 1 study 66 that demonstrated that patients on fentanyl not only had no problem driving but also had improved in several performance measures on opioids, the investigators of the remaining 3 studies suggested at minimum caution when patients on opioids are allowed to drive. Careful consideration of these 4 studies demonstrated significant limitations in the applicability of their conclusions (Table 2) .
DISCUSSION
This systematic review concluded that although most of the included studies were of fair or high methodological quality and largely used high sensitivity and well-validated cognitive and psychomotor tests, they suffered primarily from significant lack of clinically relevant information that limits the interpretation of the results, therefore their generalizability to everyday practice. The vast majority of studies paid little attention, if any, to variables that can affect cognition and psychomotor function or driving ability, commonly found in chronic pain populations.
This review differs substantially from previous reviews because it (1) included studies both on chronic cancer or noncancer pain patients on opioids that tested cognitive/ psychomotor functions by psychological tests, driving simulator, or on road driving; (2) rated all studies for quality; (3) assessed the validity and sensitivity of psychomotor/cognitive tests; and (4) scrutinized the studies for possible confounders, which could affect the generalizability of conclusions in our everyday practice.
Sleep deprivation, fatigue, or daytime somnolence may markedly interfere with aspects of human performance. 30, 32, 34 Furthermore, several studies have concluded that depression or anxiety may have a significant effects on cognitive or psychomotor performance [36] [37] [38] [39] although there is considerable variability and certain subsets of such patients may be more vulnerable. Although we did not find studies that had specifically examined the effect of such psychoemotional disturbance on driving performance, there have been multiple studies on the effects of medications used to treat psychoemotional problems. Ramaekers, 42 in a review of published studies from 1983 to 2000, found that the adverse effect of acute doses of sedating antidepressants on vehicular "weaving" were comparable to those seen in drivers with a blood alcohol concentration of 0.8 mg/mL or more. Thomas, 40 in a systematic review of studies from 1980 to 1997, concluded that the use of benzodiazepines approximately doubles the risk of motor vehicle accidents. We must stress that chronic pain patients are more likely to be on more than 1 kind of medications 47 with several of these drugs (ie, tricyclic antidepressants, sedatives, etc.) shown to impair cognitive functions, particularly in the elderly. 43, 78 Of note, the current review did not assess such psychoemotional factors as irritability, euphoria, and risk-taking behaviors that may also be associated with chronic pain, opioids, and traffic accidents.
In addition, high level of pain may also affect aspects of cognition and psychomotor function, as poorly controlled pain is known to compete with attentional resources or to impact on other aspects of cognitive functioning. had consumed alcohol achieving a blood alcohol concentration of 0.08%, 15 indicating that the complex act of driving is affected by untreated or poorly treated pain. It is important to note that Kuhajda et al 79 demonstrated that cognitive difficulties occur in pain patients when pain intensity levels exceed a threshold that varied in the 4 studies they reviewed between 64 and 71 of 100 on a 0 to 100 Numerical Rating Scale. It should also be noted that those attending tertiary care pain clinics differ from pain patients in primary care settings 80, 81 as they present with higher levels of psychosocial dysfunction and comorbidities and compensable issues. In addition, it is often the interaction and cooccurrence of confounding variables that may result in impairment. 82 Most studies in our systematic review included patients with a wide range of pain scores. Although reporting of pain levels did not earn the studies a confounding variable point, most studies did not control for either level of pain or other factors even when they mentioned them. In addition, for most studies included in our review, the dose of opioids used was extremely variable. It is unclear how high doses of opioids (ie, well over 400 mg of morphine equivalent and up to thousands of mg daily) affect cognition (even when the daily opioid dose is considered "stable"), as no studies have been conducted on patients on stable long-acting moderate versus high doses of opioids. Determination of "stable" opioid level was very difficult due to lack of definition of "stable doses" and the poor reporting of opioid doses and timing in several studies. Finally, many studies included short-acting opioids, which by themselves could alter cognition (depending on the dose, route of administration, and schedule or lack of it), though "scheduled" short-acting preparations can effectively treat chronic pain. In a double-blind, placebo-controlled, crossover study of cancer patients on slow release opioid preparations, administration of immediate release morphine produced transient anterograde and retrograde memory impairment and decrement in 2-target tracking, despite the fact that it further reduced pain. The investigators suggested that these changes may impact negatively on patients' everyday functioning. Note that all ART measures are very rarely used in North American Neuropsychology. Note that we mention cancer or no cancer patients but all studies have comparator groups of cancer or noncancer pain patients or healthy volunteers. Doses are reported in morphine or equianalgesic doses unless otherwise specified.
BDI indicates Beck Depression Inventory; HS, high sensitivity; LS, less sensitivity; M, morphine or morphine equivalents; MINORS, Methodological Index for Nonrandomized Studies; NRS, Numeric Rating Scale; VAS, Visual Analogue Scale.
As for the risk of traffic accidents in the presence of medical diseases or medications, few studies have looked specifically at patients with pain. Although a structured evidence-based systematic review 4 had presented "strong consistent evidence" that opioid users had no greater incidence of motor vehicle violation or accidents versus comparable controls, several studies have been published since furnishing evidence to the contrary. A recent epidemiological study on middle-aged workers demonstrated that pain alone or in combination with pain medications was associated with increased traffic accident risk. However, the study was unable to differentiate the effects of high levels of pain and those of analgesic drugs. 84 In 2010, a large registry-based study in the USA demonstrated increased risk of unsafe driving in female drivers aged 25 to 55 years and male drivers aged 25 to 65 years involved in fatal traffic accidents when receiving opioids. 85 However, due to the diversity of the opioid formulations detected in this study (eg, slow release vs. immediate release formulations) and missing information regarding the purpose of opioid use (eg, pain relief vs. recreational use), it is difficult to make a final judgment on the impact of opioids prescribed for pain management. The frequency of the use of immediate release opioids and the higher odds ratio for unsafe driving actions in younger drivers as compared with those aged 65 to 75 years, reduce the generalizability of the results. In addition, both the pharmacokinetics and the purpose of opioid use may impact greatly on traffic accident risk. 85 Another registry-based study in Norway 86 showed that the risk of involvement in a traffic accident was markedly increased in users of natural opium alkaloids, benzodiazepine tranquillizers, and benzodiazepine hypnotics. Coprescription of benzodiazepines has been shown to be highly prevalent and increases in parallel with the amount of prescribed opioid drugs. 78 Therefore, it might be assumed that, in the case of chronic pain patients on opioids, the risk of causing a traffic accident further increases in the presence of coprescriptions of other psychoactive drugs, poor response to treatment of pain, and impaired sleep or comorbid psychiatric disorders.
In summary, we believe that we are underreporting factors that affect the generalizability of the results on the reviewed studies. We should stress, however, that opioids alone should not be singled out. The presence of other factors that can by themselves or in conjunction with opioids results in altered cognition or driving performance, should be considered carefully in chronic pain patients.
The difficulty to create an easily applicable system regarding opioids and driving is apparent by the fact that regulations vary significantly between different countries, and even within different jurisdictions in the same country. For example, in Ontario, Canada (but not necessarily in all Canadian provinces and Canadian Territories), it is mandatory for the physician to report to the Ministry of Transportation a patient who has a condition that "may make him/her unsafe to drive." 87 Unfortunately, there are no specific guidelines advising the physicians what to do except telling the patients "not to drive" during titration of opioid dose and/or use of short-acting analgesic medications, or when they have side effects from the medications, whereas they are also told to avoid using alcohol. Warning or advising the patients not to drive, however, seems insufficient to prevent unsafe drivers from being on the road, as a recent study showed that, despite warnings regarding driving, the majority of patients who use psychotropic drugs reported they drive regularly. 88 In the United Kingdom, although there are no specific regulations concerning chronic pain and treatment with opioids, it is forbidden in general to drive under the influence of opioids and any other substance, which might impair driving. The law, however, does not distinguish between illicit drugs and prescribed medicines. On notification of a physician of possible risk, every driving license holder has the duty to notify the Driver and Vehicle Licensing Agency (DVLA), about any medical condition y which may affect safe driving, including "prospective disability" (driving safety in the future). Although such conditions might be treated with analgesics such as opioids, they are not specifically mentioned by the DVLA. If such a patient surrenders his/her license, the DVLA will not make formal medical enquiries into driving fitness. If the patient is incapable of understanding the physician's advice to surrender his driving license to DVLA, physicians may also inform the agency. 89 Of note, if a patient is involved in an accident and it is found that his/her health condition was a contributing factor, the patient may be prosecuted and the insurance may not be valid.
In Germany, driving under the influence of "recreational or street" narcotics is a legal offence, whereas patients on opioids and other centrally acting drugs for medical reasons are excluded. However, physicians must inform every patient about potential risks when prescribing psychoactive drugs. When there are major concerns about driving fitness and a patient is not willing to refrain from driving, the physician may inform the public authority, which then will be in charge of further enquiries. 90 Much higher demands concerning medical conditions, use of psychoactive substances, and psychomotor and cognitive performance tests are required for professional car drivers such as truck and bus drivers in Germany and in the United Kingdom.
Given the substantial differences in regulations pertaining to driving and psychoactive drugs, a very recent project of 19 European countries (Driving under the Influence of Drugs, Alcohol and Medicines, 2010) 91 attempts to develop an empirically based classification and categorization system that allows consistent labeling of medicines with respect to their impact on driving. One major goal of the project is to harmonize the existing differences of national conditions and health care practices and to develop prescribing and dispensing guidelines for health care professionals.
In answering the question "Can patients on opioids drive"? our study suggests that indeed certain patients on pharmacologically stable doses of opioids are able to drive provided they (1) lack coprescriptions or other substance use (alcohol and illicit drugs) that may exert significant central nervous system effects, (2) do not experience high levels of pain, (3) lack a substantial sleep disorder or daytime somnolence, and (4) do not have significant depression or anxiety disorder or other diagnosable psychiatric condition. Unfortunately, it still remains unclear what level of "stable" opioids may be considered safe to drive (as studies comparing cognitive function or driving performance of chronic pain patients on moderate doses of opioids vs. high doses of opioids do not exist). We do acknowledge that many medications for medical conditions such as diabetes, high blood pressure, coronary artery disease, chronic sinusitis, or psychological or psychiatric conditions may affect driving safety but reporting on these individually is beyond the scope of this study.
A word of caution: systematic reviews such as this study, attempt to guide evidence-based medical practice. However, evidence-based medicine is "about tools, not about rules" and is not meant to take away expertise and judgment on behalf of the physician. We stress, therefore, that the prescribing physician ultimately should retain and exercise his/her judgment as each patient should be considered individually.
The results of our study resonate with the recent excellent review by Chapman et al. 92 These authors pointed out the need to show "effectiveness" of long-term opioid therapy in actual everyday practice, reiterated that opioid therapy is "usually embedded" in combination therapy and pointed out the great need for future studies relating to the interaction of opioids with other medications, dietary supplements, alcohol, and licit or illicit drugs used recreationally as there is limited information to guide physicians concerned regarding chronic non cancer pain polypharmacy and nonopioid drug administration that may interfere with the assessment of opioid effectiveness and drug-drug interactions.
To assess the effects of opioids on driving in a population with chronic pain, future studies need to strive for balance between internal validity (risk of bias) and external validity (generalizability). Studies conducted with healthy volunteers, in experimental settings where pain is artificially induced have very little generalizability to the population where the results will be applied. Studies conducted in administrative databases are useful to raise hypothesis about association of opioids and traffic accidents, but they usually have very little information with regard to type of opioids, dose, route of administration, comorbidities, and co-interventions. Neuropsychological or related cognitive/psychomotor tests may provide useful surrogate measures of driving performance, but they need to be validated further, especially in "borderline" cases in which it is not a clear-cut decision about whether a person should or should not be driving. Driving simulators can vary in terms of visual and auditory input and sophistication, but a major problem is the high drop-out due to motion sickness. On-road driving tests are generally considered the gold standard for driving evaluation, but they may not simulate all situations faced in real driving and may not take into account various individual variables. We consider that the gold standard for the evaluation of driving risk is the incidence of actual traffic accidents involving opioid use. We have included a couple of such studies in the study and we have pointed out to some problems, as such studies may suffer from a decision about the risk versus benefits of allowing persons who are taking opioids to drive.
Future studies should look at the effects of opioids on driving as the primary research question, and use a study design that offers low risk of bias, such as a randomized, controlled trial with blinded outcome assessors, and analyses that take into consideration the most relevant confounders in this area. In addition, such studies should provide evidence that (1) the prescribed drug(s) are present and (2) there is absence of other nonprescribed legal or illegal substances, through confirmatory drug testing. Finally, studies with only short-acting opioids should also be considered, as in real life there are many patients who take 3 to 4 short-acting opioid preparations daily and can be very productive and manage their pain well. However, and until such studies can be conducted, the present systematic review offers some guidance to the practicing physicians at least in relationship to those patients on longterm opioid therapy who are fairly safe to drive.
